UGNasdaqPerfumes, Cosmetics & Other Toilet PreparationsUS GAAP · USD

United-Guardian, Inc

United-Guardian is a U.S.-based specialty ingredients company that develops and manufactures cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients through its Guardian Laboratories division. Its products are sold through distributors and direct customers across North America, Europe, Asia, and other international markets.

Liikevaihto10,5milj. USD
−13,4 %v/v
Liikevoitto (EBIT)2,2milj. USD
−38,5 %v/v
EBIT-marginaali21,3%
−8,7 %-yks.v/v
Nettotulos2,1milj. USD
−35,2 %v/v
Vapaa kassavirta1,9milj. USD
−37,1 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

051015milj. USD2020: 11 milj. USD2020: EBIT 3,6 milj. USD20202021: 14 milj. USD2021: EBIT 5,7 milj. USD20212022: 13 milj. USD2022: EBIT 4,0 milj. USD20222023: 11 milj. USD2023: EBIT 2,9 milj. USD20232024: 12 milj. USD2024: EBIT 3,6 milj. USD20242025: 11 milj. USD2025: EBIT 2,2 milj. USD2025112,2
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Cosmetic Ingredients45 %

Specialty ingredients used in personal care and cosmetic formulations.

Medical Lubricants30 %

Lubricant products used in medical and healthcare applications.

Pharmaceutical Ingredients15 %

Ingredients and specialty products sold into pharmaceutical uses.

Sexual Wellness Ingredients10 %

Ingredients marketed for sexual wellness applications, including Natrajel.

Tuotteet

Raportoitu · osuus liikevaihdosta
51,5%28,5%20,0%FY2025100 %
  • Pharmaceuticals51,5 %
  • Cosmetic Ingredients28,5 %
  • Medical Lubricants20,0 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

United-Guardian sells primarily to distributors, who then serve regional and end-market customers in personal care, medical, and specialty chemical channels. It also sells directly to some customers, including U.S.-based cosmetic ingredient buyers, and its products are used by formulators that incorporate them into finished goods. Demand depends on formulation needs, product performance, and distributor reach into specific territories.

Distributors

Buy specialty ingredients for resale into regional personal care, medical, and chemical markets.

Cosmetic formulators

Use cosmetic ingredients in finished personal care products and buy for performance and quality.

Medical product customers

Buy medical lubricants and related products for healthcare applications and formulations.

Pharmaceutical customers

Purchase specialty ingredients used in pharmaceutical applications and formulations.

Sexual wellness channel partners

Distributors and customers that will market and use Natrajel ingredients in sexual wellness products.

Strategia

United-Guardian is expanding distribution coverage to reach more end markets and territories for its specialty ingredient portfolio. It is also developing new product lines and market opportunities, including sexual wellness and broader medical applications, while monitoring supply-chain and tariff exposure that can affect competitiveness.

Expand distribution channelsLyhyt aikaväli

Broader distributor coverage increases market access without building a large direct sales force.

Launch and commercialize new product linesKeskipitkä aikaväli

New products can open adjacent end markets and diversify the revenue base.

Strengthen specialty product differentiationKeskipitkä aikaväli

Unique formulations help defend against lower-cost Asian competitors.

Maantiede

Q1/2026

The company is based in the United States, where it also serves direct customers and a portion of its distributor network. Its commercial reach extends through North America, the UK and Ireland, South Korea, and parts of Latin America via distribution partners, while supply-chain exposure includes China-linked sourcing and end-market demand. Geography matters because tariff policy, distributor coverage, and regional competition can affect both sales access and product competitiveness.

USA78 %
Other countries (US filing)22 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

The company faces tariff, trade-policy, and supply-chain risk because a meaningful portion of its sales and sourcing is tied to China-linked flows. It also competes against lower-cost Asian manufacturers, which can pressure pricing and demand if customers substitute cheaper alternatives. As a specialty ingredients business, it is exposed to distributor concentration, customer ordering timing, and the execution risk of new product commercialization.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Tariff and trade-policy exposure, especially China1Competition from lower-cost Asian manufacturers2
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Tariff and trade-policy exposure, especially ChinaVaikutus: KorkeaTodennäköisyys: Korkea

    A significant amount of cosmetic ingredient and medical lubricant sales rely on shipments to China, and tariffs can make products less competitive.

    Kohdistuu: China-linked sales and customer demand

  2. Competition from lower-cost Asian manufacturersVaikutus: KorkeaTodennäköisyys: Korkea

    Competitors can offer similar products at lower prices, which can pressure volumes and pricing.

    Kohdistuu: Cosmetic ingredients and related specialty products

  3. Distributor concentration and ordering volatilityVaikutus: Keskitaso

    Sales depend on distributor inventory cycles and customer timing, which can create quarter-to-quarter swings.

    Kohdistuu: ASI and other distributors

  4. Commercialization delay for new productsVaikutus: Keskitaso

    Delayed manufacturing or customer adoption can push out expected revenue from new lines.

    Kohdistuu: Natrajel sexual wellness ingredients

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition

Shipment timing and distributor orders can change when sales are recorded and make quarterly results uneven.

Vaikutus: Affects reported net sales and period-to-period comparability

Credit loss allowance

The company estimates expected collectability on receivables from distributors and direct customers.

Vaikutus: Affects bad debt expense and net receivables

Inventory valuation

Specialty ingredients can become excess or slow-moving if customer demand shifts or orders are delayed.

Vaikutus: Affects cost of sales and inventory carrying value

Marketable securities and investment income

Cash is invested in securities, so interest rates and portfolio size affect non-operating income.

Vaikutus: Affects investment income and balance-sheet asset mix

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 24.9.2026

United-Guardian, Inc (UG) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo